

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Substitute for form 1449A/PTO**

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT** **TC 21 200**

*(use as many sheets as necessary)*



<i>Complete if Known</i>	
Application Number	10/589,754
Filing Date	August 17, 2006
First Named Inventor	Irvin R COHEN et al
Art Unit	unknown
Examiner Name	unknown

Sheet 1 of 1

Attorney Docket Number	32522
------------------------	-------

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of copy of this form with next communication to  
1. Applicant's unique citation designation number (optional):

Applicant's unique citation designation number (optional).

<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information

process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known	
Application Number	10/589,754
Filing Date	August 17, 2006
First Named Inventor	Irun R COHEN et al
Group Art Unit	unknown
Examiner Name	unknown

Sheet 2 Of 5 Attorney Docket Number 32522

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	6	Akisawa et al. "High Levels of Ezrin Expressed by Human Pancreatic Adenocarcinoma Cell Lines With High Metastatic Potential", Biochemical and Biophysical Research Communications, 258: 395-400, 1999.	
	7	Ariel et al. "Cell Surface-Expressed Moesin-Like Receptor Regulates T Cell Interactions With Tissue Component and Binds An Adhesion-Modulating IL-2 Peptide Generated by Elastase", The Journal of Immunology, 166: 3052-3060, 2001.	
	8	Barna et al. "Activation of Type III Nitric Oxide Synthase in Astrocytes Following A Neurotropic Viral Infection", Virology, 223: 331-343, 1996.	
	9	Berge et al. "Pharmaceutical Salts", Journal of Pharmaceutical Sciences, 66(1): 1-19, 1977.	
	10	Blau et al. "Entry and Release of Measles Virus Are Polarized in Epithelial Cells", Virology, 210: 91-99, 1995.	
	11	Carmeci et al. "Moesin Expression Is Associated With the Estrogen Receptor-Negative Breast Cancer Phenotype", Surgery, 124: 211-217, 1998.	
	12	Chowers et al. "Disaccharides Derived From Heparin of Heparan Sulfate Regulate IL-8 and IL-1 $\beta$ Secretion by Intestinal Epithelial Cells", Gastroenterology, 120: 449-459, 2001.	
	13	Clark et al. "A Model to Study Viral and Cytokine Involvement in Sjögren's Syndrome", Autoimmunity, 18: 7-14, 1994.	
	14	Dobbs et al. "Neuroendocrine Regulation of Cytokine Production During Experimental Influenza Viral Infection", The Journal of Immunology, 157: 1870-1877, 1996.	
	15	Eugène et al. "Microvilli-Like Structures Are Associated With the Internalization of Virulent Capsulated Neisseria Meningitidis Into Vascular Endothelial Cells", Journal of Cell Science, 155(6): 1231-1241, 2002.	
	16	Fukuda et al. "Acute Measles Infection in the Hamster Cochlea", Acta Otolaryngologica, Suppl.514: 111-116, 1994.	
	17	Guan et al. "Effects of Ezrin on Differentiation and Adhesion of Hepatocellular Carcinoma", Chinese Journal of Cancer, Ai Zheng, 21(3): 281-284, 2002.	
	18	Haas et al. "Binding Partners L1 Cell Adhesion Molecule and the Ezrin-Radixin-Moesin (ERM) Proteins Are Involved in Development and the Regenerative Response to Injury of Hippocampal and Cortical Neurons", European Journal of Neuroscience, 20: 1436-1444, 2004.	
Examiner Signature		Date Considered	

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT***(use as many sheets as necessary)***Complete if Known**

Application Number	10/589,754
Filing Date	August 17, 2006
First Named Inventor	Irun R COHEN et al
Art Unit	unknown
Examiner Name	unknown

Sheet 3 Of 5 Attorney Docket Number 32522

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	19	Harrison et al. "Distribution and Expression of CD44 Isoforms and Ezrin During Prostate Cancer-Endothelium Interaction", International Journal of Oncology, 21: 935-940, 2002.	
	20	Hecker et al. "Specific Binding of HIV-1 Envelope Protein Gp120 to the Structural Membrane Proteins Ezrin and Moesin", Virus Research, 49: 215-223, 1997.	
	21	Helms et al. "A Putative RUNX1 Binding Site Variant Between SLC9A3R1 and NAT9 Is Associated With Susceptibility to Psoriasis", Nature Genetics, 35(4): 299-356, 2003.	
	22	Hershkoviz et al. "Disaccharides Generated From Heparan Sulphate or Heparin Modulate Chemokine-Induced T-Cell Adhesion to Extracellular Matrix", Immunology, 99: 87-93, 2000.	
	23	Hirasawa et al. "Possible Role of Macrophage-Derived Soluble Mediators in the Pathogenesis of Encephalomyocarditis Virus-Induced Diabetes in Mice", Journal of Virology, 71(5): 4024-4031, 1997.	
	24	Hoe et al. "Insight Into Molecular Basis of Pathogen Abundance: Group A Streptococcus Inhibitor of Complement Inhibits Bacterial Adherence and Internalization Into Human Cells", Proc. Natl. Acad. Sci. USA, 99(11): 7646-7651, 2002.	
	25	Ichikawa et al. "Expression of Moesin and Its Associated Molecule CD44 in Epithelial Skin Tumors", Journal of Cutaneous Pathology, 25: 237-243, 1998.	
	26	Ichikawa et al. "Moesin and CD44 Expression in Cutaneous Melanocytic Tumours", British Journal of Dermatology, 138: 763-768, 1998.	
	27	John et al. "Interleukin-1 $\beta$ Induces A Reactive Astroglial Phenotype Via Deactivation of the Rho GTPase-Rock Axis", The Journal of Neuroscience, 24(11): 2837-2845, 2004.	
	28	Kobayashi et al. "Clinical Significance of Cellular Distribution of Moesin in Patients With Oral Squamous Cell Carcinoma", Clinical Cancer Research, 10: 572-580, 2004.	
	29	Kobayashi et al. "Shifts in Cellular Localization of Moesin in Normal Oral Epithelium, Oral Epithelial Dysplasia, Verrucous Carcinoma and Oral Squamous Cell Carcinoma", Journal of Oral and Pathological Medicine, 32: 344-349, 2003.	
Examiner Signature		Date Considered	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

*Complete if Known*

Application Number	10/589,754
Filing Date	August 17, 2006
First Named Inventor	Irun R COHEN et al
Art Unit	unknown
Examiner Name	unknown

Sheet	4	Of	5	Attorney Docket Number	32522
-------	---	----	---	------------------------	-------

## OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	30	Kudlacz et al. "Parainfluenza Virus Type-3 Infection Attenuates the Respiratory Effects of Antigen Challenge in Sensitized Guinea Pigs", Inflammatory Research, 44: 105-110, 1995.	
	31	Lankes et al. "Moesin: A Member of the Protein 4.1-Talin-Ezrin Family of Proteins", Proc. Natl. Acad. Sci. USA, 88(19): 8297-8301, 1991.	
	32	Lara-Pezzi et al. "The Hepatitis B Virus X Protein (HBx) Induces A Migratory Phenotype in A CD44-Dependent Manner: Possible Role of HBx in Invasion and Metastasis", Hepatology, 33(5): 1270-1281, 2001.	
	33	Lubec et al. "Manifold Reduction of Moesin in Fetal Down Syndrome Brain", Biochemical and Biophysical Research Communications, 286: 1191-1194, 2001.	
	34	Marecko et al. "Ezrin/Radixin/Moesin Proteins Are High Affinity Targets for ADP-Ribosylation by Pseudomonas Aeruginosa ExoS", The Journal of Biological Chemistry, 279(37): 38402-38408, 2004.	
	35	Martin et al. "The Role of the CD44/Ezrin Complex in Cancer Metastasis", Critical Reviews in Oncology/Hematology, 46: 165-186, 2003.	
	36	Masot et al. "Pathological Study of Experimentally Induced Bovine Respiratory Syncytial Viral Infection in Lambs", Journal of Veterinary Medicine, B43: 233-243, 1996.	
	37	Morgan et al. "Retrovirus Infection: Effect of Time and Target Cell Number", Journal of Virology, 69(11): 6994-7000, 1995.	
	38	Morishige et al. "Adenovirus-Mediated Transfer of Dominant-Negative Rho-Kinase Induces A Regression of Coronary Arteriosclerosis in Pigs In Vivo", Arteriosclerosis, Thrombosis, and Vascular Biology, 21: 548-554, 2001.	
	39	Olsson et al. "MIR Is A Novel ERM-Like Protein That Interacts With Myosin Regulatory Light Chain and Inhibits Neurite Outgrowth", The Journal of Biological Chemistry, 274(51): 36288-36292, 1999.	
	40	Orange et al. "An Absolute and Restricted Requirement for IL-12 in Natural Killer Cell IFN- $\gamma$ Production and Antiviral Defense", The Journal of Immunology, 156: 1138-1142, 1996.	
	41	Raney et al. "Members of the Nuclear Receptor Superfamily Regulate Transcription From the Hepatitis B Virus Nucleocapsid Promoter", Journal of Virology, 71(20): 1058-1071, 1997.	
Examiner Signature		Date Considered	

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.  
Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.<sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT***(use as many sheets as necessary)***Complete if Known**

Application Number	10/589,754
Filing Date	August 17, 2006
First Named Inventor	Irun R COHEN et al
Art Unit	unknown
Examiner Name	unknown

Sheet 5 Of 5 Attorney Docket Number 32522

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	42	Sagara et al. "Cellular Actin-Binding Ezrin-Radixin-Moesin (ERM) Family Proteins Are Incorporated Into the Rabies Virion and Closely Associated With Viral Envelope Proteins in the Cell", <i>Virology</i> , 206: 485-494, 1995.	
	43	Selbach et al. "The Helicobacter Pylori CagA Protein Induces Tyrosine Dephosphorylation of Ezrin", <i>Proteomics</i> , 4: 2961-2968, 2004.	
	44	Selin et al. "Reduction of Otherwise Remarkably Stable Virus-Specific Cytotoxic T Lymphocyte Memory by Heterologous Viral Infections", <i>Journal of Experimental Medicine</i> , 183: 2489-2499, 1996.	
	45	Serrador et al. "Moesin Interacts With the Cytoplasmic Region of Intercellular Adhesion Molecule-3 and Is Redistributed to the Uropod of T Lymphocytes During Cell Polarization", <i>Journal of Cell Biology</i> , 138(6): 1409-1423, 1997.	
	46	Skoudy et al. "A Functional Role for Ezrin During <i>Shigella Flexneri</i> Entry Into Epithelial Cells", <i>Journal of Cell Science</i> , 112: 2059-2068, 1999.	
	47	Stark et al. "Infection of A549 Cells With A Recombinant Adenovirus Vector Induces ICAM-1 Expression and Increased CD-18-Dependent Adhesion of Activated Neutrophils", <i>Human Gene Therapy</i> , 7: 1669-1681, 1996.	
	48	Stemmer-Rachamimov et al. "Expression of NF2-Encoded Merlin and Related ERM Family Proteins in the Human Central Nervous System", <i>Journal of Neuropathology and Experimental Neurology</i> , 56(6): 735-742, 1997.	
	49	Tokunou et al. "Altered Expression of the ERM Proteins in Lung Adenocarcinoma", <i>Laboratory Investigation</i> , 80(11): 1643-1650, 2000.	
	50	Tsukita et al. "ERM Family Members as Molecular Linkers Between the Cell Surface Glycoprotein CD44 and Actin-Based Cytoskeletons", <i>The Journal of Cell Biology</i> , 126(2): 391-401, 1994.	
	51	Wainberg et al. "Modulation of Stress Protein (Hsp27 and Hsp70) Expression in CD+ Lymphocytic Cells Following Acute Infection With Human Immunodeficiency Virus Type-1", <i>Virology</i> , 233: 364-373, 1997.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional).

<sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

<sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

<sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.